These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12392585)

  • 1. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
    de Maat MM; Huitema AD; Mulder JW; Meenhorst PL; van Gorp EC; Beijnen JH
    Br J Clin Pharmacol; 2002 Oct; 54(4):378-85. PubMed ID: 12392585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
    Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race is not associated with nevirapine pharmacokinetics.
    de Maat MM; Nellen JF; Huitema AD; Wit FW; Mulder JW; Prins JM; Beijnen JH
    Ther Drug Monit; 2004 Aug; 26(4):456-8. PubMed ID: 15257078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
    Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
    Moltó J; Valle M; Miranda C; Cedeño S; Miranda J; Santos JR; Negredo E; Vilaró J; Costa J; Clotet B
    J Antimicrob Chemother; 2008 Oct; 62(4):784-92. PubMed ID: 18593723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of nevirapine in Thai HIV-infected patients.
    Wattanakul T; Avihingsanon A; Manosuthi W; Punyawudho B
    Antivir Ther; 2014; 19(7):651-60. PubMed ID: 24504545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.
    Dailly E; Raffi F; Perré P; Martin J; Deslandes G; Jolliet P
    HIV Med; 2009 Oct; 10(9):586-9. PubMed ID: 19486187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
    Mustafa S; Yusuf WN; Woillard JB; Choon TS; Hassan NB
    Eur J Clin Pharmacol; 2016 Jul; 72(7):831-8. PubMed ID: 27025609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.
    Sabo JP; Lamson MJ; Leitz G; Yong CL; MacGregor TR
    AAPS PharmSci; 2000; 2(1):E1. PubMed ID: 11741217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
    AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
    Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study.
    Bart G; Giang LM; Yen H; Hodges JS; Brundage RC
    Drug Alcohol Depend; 2021 Oct; 227():109025. PubMed ID: 34482033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    Zhou XJ; Sheiner LB; D'Aquila RT; Hughes MD; Hirsch MS; Fischl MA; Johnson VA; Myers M; Sommadossi JP
    Antimicrob Agents Chemother; 1999 Jan; 43(1):121-8. PubMed ID: 9869576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
    Dickinson L; Chaponda M; Carr DF; van Oosterhout JJ; Kumwenda J; Lalloo DG; Pirmohamed M; Heyderman RS; Khoo SH
    Antimicrob Agents Chemother; 2014; 58(2):706-12. PubMed ID: 24217698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.
    Vreeman RC; Nyandiko WM; Liechty EA; Busakhala N; Bartelink IH; Savic RM; Scanlon ML; Ayaya SO; Blaschke TF
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):277-86. PubMed ID: 25140906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
    Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
    De Maat MM; Mathôt RA; Veldkamp AI; Huitma AD; Mulder JW; Meenhorst PL; Van Gorp EC; Carlier H; Beijnen JH
    Pharmacol Res; 2002 Sep; 46(3):295-300. PubMed ID: 12220974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.